U.S. senior citizens are filling fewer prescriptions for drugs as out-of-pocket costs rise in a weak economy, undercutting a record level of new product introductions by drug companies, industry researchers said.
Dispensed prescriptions to patients 65 and older declined 3.1 percent in 2011, compared with a 2.7 percent dip in 2010, according to a study released today by the IMS Institute for Healthcare Informatics in Parsippany, New Jersey. For all age groups, prescriptions fell 1.1 percent last year.
The economy and increased cost-sharing requirements are causing people to make fewer doctor visits and fill fewer orders for pills, IMS said. There probably won’t be improvement in 2012 as the economic recovery and population growth aren’t moving fast enough to boost spending on brand-name drugs, said Michael Kleinrock, the institute’s research development director.
Read the full story: http://hcp.lv/Hjhu4m
Source: Bloomberg
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More